Claims for Patent: 7,097,860

Summary for Patent: 7,097,860

Title:	Method and composition for treatment of inflammatory and inflammation-related disorders
Abstract:	A method of reducing inflammation in a variety of disorders by using an intraperitoneal solution of magnesium. The solution can be used for treating inflammatory and inflammation-related disorders in animals and/or humans. Application of the solution reduces inflammation and thereby assists in the healing process. An alternative method involves the intraperitoneal administration of a solution containing magnesium salts. Another alternative method provides for treatment of inflammatory and inflammation-related disorders in animals by way of intraperitoneal administration of a solution containing magnesium salts, methenamine or its salts and dextrose. The method further provides the use of methenamine or its salts and/or dextrose in combination with magnesium.
Inventor(s):	Moshenyat; Aaron (Boca Raton, FL), Moshenyat; Anna (Boca Raton, FL), Moshenyat; Reuven (New York City, NY), Moshenyat; Yitzchak (New York City, NY)
Assignee:
Application Number:	10/146,735
Patent Claims:	1. A method of treating inflammation in mammals by intraperitoneally administering substantial amounts of magnesium salts into the intraperitoneal cavity for absorption by the mammal to accelerate the natural healing process in the mammal, including the steps of: forming a solution which contains magnesium salts in a range of approximately 1.2% to 12% W/V; and intraperitoneally administering an amount of the solution to a mammal in need of treatment for inflammation, so that the magnesium is absorbed into the mammal via the intraperitoneal cavity in substantial quantities (i) which would be toxic for that mammal's body weight if administered via intravenous or intramuscular injection, and (ii) which are effective to raise the level of magnesium in the mammal's body to a higher than normal level of magnesium, wherein said higher than normal level of magnesium is utilized by the mammal to produce increased levels of adenosine triphosphate which carry chemical energy throughout the mammal's body and which is used in the normal cellular level process of reducing inflammation; whereby the reduction of inflammation in the treated mammal is accelerated by absorption via the intraperitoneal said of substantial quantities of magnesium salts into the mammal which in turn raises the magnesium level in the body to a higher than normal level. 2. A method, as in claim 1, including the additional step of adding methenamine, methenamine hippurate, or methenamine mandelate, to the solution. 3. A method, as in claim 2, wherein the methenamine, methenamine hippurate, or methenamine mandalate is added in a range of approximately 1% to 12% W/V to the solution. 4. A method, as in claim 3, including the additional step of adding dextrose to the solution. 5. A method, as in claim 4, wherein the dextrose is added in a range of approximately 1% to 5% WN to the solution. 6. A method, as in claim 3, including the additional steps of: preparing the solution for each 500 kilograms of body weight in the following proportions: dissolving approximately 3 20 grams of magnesium salts in approximately 230 ml of solution; adding approximately 2.5 12.5 grams of dextrose; sterilizing the solution; cooling the solution to a temperature of approximately 25 30 degrees Celsius; adding approximately 2.5 30 grams of methenamine salts; and adding sterile water to bring the total solution volume to approximately 250 ml. 7. A method, as in claim 6, including the additional step of sterilizing the solution by heating it to approximately 100 degrees Celsius for approximately 30 minutes. 8. A method, as in claim 1, including the additional step of adding dextrose to the solution. 9. A method, as in claim 8, wherein dextrose is added in a range of approximately 1% to 5% W/V to the solution. 10. A method, as in claim 1, including the additional step of using distilled water as the solvent of the solution. 11. A method, as in claim 10, including the additional step of adding methenamine, methenamine hippurate, or methenamine mandelate, in a range of approximately 1% to 12% W/V to the solution. 12. A method, as in claim 11, including the additional step of adding dextrose to the solution. 13. A method, as in claim 12, wherein the dextrose is added in a range of approximately 1% to 5% W/V to the solution. 14. A method, as in claim 10, including the additional step of adding dextrose in a range of approximately 1% to 5% W/V to the solution. 15. A method, as in claim 1, including the additional step of using a saline solution as the solvent of the solution. 16. A method, as in claim 15, wherein the saline solution is 0.1 to 0.9% W/V sodium chloride. 17. A method, as in claim 15, including the additional step of adding dextrose in a range of approximately 1% to 5% W/V to the solution. 18. A method, as in claim 1, wherein the magnesium salt is magnesium sulfate, magnesium sulfate heptahydrate, or epsom salts. 19. A method, as in claim 1, wherein the solution is obtained by adding a sufficient amount of magnesium salts to a Ringer's solution. 20. A method, as in claim 1, wherein the magnesium salt is MgCl.sub.2, or MgCl.sub.2.6H.sub.2O. 21. A method of treating inflammation in mammals by intraperitoneally administering substantial amounts of magnesium salts into the intraperitoneal cavity for absorption by the mammal to accelerate the natural healing process in the mammal, including the steps of: forming a solution which contains magnesium salts in a range of approximately 1.2% to 12% WN and methenamine or its salts in a range of approximately 1% to 12% W/V; and intraperitoneally administering the solution to a mammal in need of treatment for inflammation, so that the magnesium is absorbed into the mammal via the intraperitoneal cavity insubstantial quantities (i) which would beloxic for that mammal's body weight if administered via intravenous or intramuscular injection, and (ii) which are effective to raise the level of magnesium in the mammal's body to a higher than normal level of magnesium, wherein said higher than normal level of magnesium is utilized by the mammal to produce increased levels of adenosine triphosphate which is used in the normal cellular level process of reducing inflammation; whereby the reduction of inflammation is accelerated by absorption via the intraperitoneal cavity of said substantial quantities of magnesium salts into the mammal which in turn raises the magnesium level in the body to a higher than normal level. 22. A method, as in claim 21, including the additional step of adding dextrose in a range of approximately 1% to 5% W/V to the solution. 23. A method, as in claim 21, wherein the methenamine salts are methenamine hippurate or methenamine mandelate in a range of approximately 1% to 12% W/V to the solution.

Details for Patent 7,097,860

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2021-08-03